Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib

Welslau M, Fasching P, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, Zahn MO, Lex B, Uleer C, Deuerling N, Hesse T, Langanke D, Häberle L, Tesch H (2026)

Publication Type: Journal article

Publication year: 2026

Journal

The Breast Elsevier

Book Volume: 85

Article Number: 104684

DOI: 10.1016/j.breast.2025.104684

Abstract

Introduction: Therapy adherence is critical, particularly for patients with breast cancer undergoing oral endocrine therapies. The use of combination regimes, such as CDK4/6 inhibitors, has introduced additional side effects, which can affect adherence. A structured patient coaching and communication tool may positively affect therapy adherence. Methods: The IMPACT study (NCT04030728) was a randomized trial including patients with advanced breast cancer (aBC) receiving abemaciclib as part of routine clinical care. The study examined the influence of structured coaching on patient adherence. Participants were randomized to receive therapy management incorporating the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool (MOATT©) or local standard of care practice (LSOC). The primary endpoint was the persistence rate at week 24 (PR24). Secondary endpoints included time to therapy discontinuation (TTD) and quality of life. Results: A total of 201 patients were randomized and initiated abemaciclib therapy. By week 24, 22 (10.9 %) patients had permanently discontinued abemaciclib for reasons other than progression or death: 14 (14.1 %) in the LSOC arm and 8 (7.8 %) in the MOATT© arm. PR24 was 68.9 % (95 % CI: 58.3–78.2) in the LSOC arm and 81.6 % (95 % CI: 72.5–88.7) in the MOATT© arm, yielding an odds ratio of 2.01 (95 % CI: 1.02–3.96; P = 0.04). TTD showed a hazard ratio of 0.59 (95 % CI: 0.32–1.07), favoring the MOATT© arm. No significant differences in quality of life between study arms were observed. Conclusion: Individual patient coaching based on MOATT© demonstrated improved PR24 for patients undergoing abemaciclib treatment for aBC.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe Sabrina Uhrig Department of Obstetrics and Gynaecology Lothar Häberle Department of Obstetrics and Gynaecology

Involved external institutions

Klinikum Fichtelgebirge DE Germany (DE) Agaplesion Diakonieklinikum Rotenburg DE Germany (DE) St.Elisabeth-Krankenhaus Leipzig DE Germany (DE) Agaplesion Markus Krankenhaus DE Germany (DE) Klinikum Aschaffenburg-Alzenau DE Germany (DE) Onkologie UnterEms DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) MVZ Landshut - Dr. med. Ursula Vehling-Kaiser DE Germany (DE) MVZ Onkologische Kooperation Harz DE Germany (DE)

How to cite

APA:

Welslau, M., Fasching, P., Semmler-Lins, N., Mueller, L., Belleville, E., Rieger, L.,... Tesch, H. (2026). Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib. The Breast, 85. https://doi.org/10.1016/j.breast.2025.104684

MLA:

Welslau, Manfred, et al. "Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib." The Breast 85 (2026).

BibTeX: Download